



May 8, 2014

## **Ophthotech Corporation to Announce First Quarter 2014 Financial Results and Host Conference Call on Tuesday, May 13, 2014**

NEW YORK--(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq:OPHT) today announced that it will release its financial results for the first quarter ended March 31, 2014, on Tuesday, May 13, 2014. Following the announcement, Ophthotech's management will host a live conference call and webcast at 8:00 a.m. Eastern Time to discuss Ophthotech's financial results for the first quarter and provide a general business update.

To participate in this conference call, dial 888-438-5535 (USA) or 719-457-2727 (International), and enter passcode 7962682. A live, listen-only audio webcast of the conference call can be accessed on the Investor Relations section of the Ophthotech website at: [www.ophthotech.com](http://www.ophthotech.com). A replay will be available approximately two hours following the live call for one week. The replay number will be 888-203-1112 (USA) or 719-457-0820 (International), passcode 7962682. A replay of the audio webcast will be accessible at: [www.ophthotech.com](http://www.ophthotech.com).

### **About Ophthotech Corporation**

Ophthotech is a biopharmaceutical company specializing in the development of novel therapeutics to treat diseases of the eye, with a focus on developing innovative therapies for age-related macular degeneration (AMD). Ophthotech's most advanced product candidate, Fovista™ an<sup>®</sup>PDGF therapy, is in Phase 3 clinical trials for use in combination with anti-VEGF drugs for the treatment of wet AMD. Ophthotech's second product candidate Zimura™, an inhibitor of complement factor C5, is being developed for the treatment of dry and wet forms of AMD. For more information, please visit [www.ophthotech.com](http://www.ophthotech.com).

### **Forward-Looking Statements**

*Any statements in this press release about Ophthotech's future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Any forward-looking statements represent Ophthotech's views only as of the date of this press release. Ophthotech anticipates that subsequent events and developments will cause its views to change. While Ophthotech may elect to update these forward-looking statements at some point in the future, Ophthotech specifically disclaims any obligation to do so.*

OPHT-G

### **Investors**

Ophthotech Corporation  
Kathy Galante, 212-845-8231  
Vice President, Investor Relations and  
Corporate Communications  
[kathy.galante@ophthotech.com](mailto:kathy.galante@ophthotech.com)

or

### **Media**

SmithSolve LLC on behalf of Ophthotech Corporation  
Jarrod Aldom, 973-442-1555 ext. 112  
[jarrod.aldom@smithsolve.com](mailto:jarrod.aldom@smithsolve.com)

Source: Ophthotech Corporation

News Provided by Acquire Media